Songxue Tao1, Guimei Li, Qian Wang, Yanyan Hu. 1. Department of Pediatrics, Shandong Provincial Hospital affiliated to Shandong University, 9677 Jingshi Road, Jinan, 250014, People's Republic of China.
Abstract
OBJECTIVE: To explore the efficacy and safety of medium dose of recombinant human growth hormone (rhGH) in the treatment of prepubescent girls with idiopathic short stature (ISS). METHODS:Fifty-one prepubescent girls with ISS were recruited into the study and divided into the treatment group (n = 27) and the control group (n = 24) depending on whether or not they accepted rhGH therapy respectively. A therapeutic dose of 0.35-0.42 mg of rhGH·(kg·wk)(-1) was administered for 2 y. The control group patients did not receive rhGH treatment. The height, growth rate, height standard deviation score (HtSDS), bone age (BA), the expected adult height (PAH), and potential side effects of rhGH treatment were analysed and compared between the groups. RESULTS: The growth rate and htSDS during years 1 and 2 were significantly higher in the treatment group than in the control group. The expected adult height was significantly higher after 2 y of treatment as compared to the corresponding value in the control group. The BA after years 1 and 2 did not significantly differ between the two groups. CONCLUSIONS: Thus, short-term therapy with a medium dose of rhGH was found to have a precise effect on prepubertal children with ISS. At this dose, it can significantly increase the growth rate of children and improve the expected adult height without accelerating bone maturation. No serious adverse reactions were found in association with rhGH use during the two-year study period.
RCT Entities:
OBJECTIVE: To explore the efficacy and safety of medium dose of recombinant humangrowth hormone (rhGH) in the treatment of prepubescent girls with idiopathic short stature (ISS). METHODS: Fifty-one prepubescent girls with ISS were recruited into the study and divided into the treatment group (n = 27) and the control group (n = 24) depending on whether or not they accepted rhGH therapy respectively. A therapeutic dose of 0.35-0.42 mg of rhGH·(kg·wk)(-1) was administered for 2 y. The control group patients did not receive rhGH treatment. The height, growth rate, height standard deviation score (HtSDS), bone age (BA), the expected adult height (PAH), and potential side effects of rhGH treatment were analysed and compared between the groups. RESULTS: The growth rate and htSDS during years 1 and 2 were significantly higher in the treatment group than in the control group. The expected adult height was significantly higher after 2 y of treatment as compared to the corresponding value in the control group. The BA after years 1 and 2 did not significantly differ between the two groups. CONCLUSIONS: Thus, short-term therapy with a medium dose of rhGH was found to have a precise effect on prepubertal children with ISS. At this dose, it can significantly increase the growth rate of children and improve the expected adult height without accelerating bone maturation. No serious adverse reactions were found in association with rhGH use during the two-year study period.
Authors: Michael B Ranke; Anders Lindberg; David A Price; Feyza Darendeliler; Kerstin Albertsson-Wikland; Patrick Wilton; Edward O Reiter Journal: Horm Res Date: 2007-01-16
Authors: P E Clayton; S Cianfarani; P Czernichow; G Johannsson; R Rapaport; A Rogol Journal: J Clin Endocrinol Metab Date: 2007-01-02 Impact factor: 5.958
Authors: Charmian A Quigley; Anne M Gill; Brenda J Crowe; Kristen Robling; John J Chipman; Susan R Rose; Judith L Ross; Fernando G Cassorla; Anne M Wolka; Jan M Wit; Lyset T M Rekers-Mombarg; Gordon B Cutler Journal: J Clin Endocrinol Metab Date: 2005-05-17 Impact factor: 5.958
Authors: Ellen Werber Leschek; Susan R Rose; Jack A Yanovski; James F Troendle; Charmian A Quigley; John J Chipman; Brenda J Crowe; Judith L Ross; Fernando G Cassorla; Werner F Blum; Gordon B Cutler; Jeffrey Baron Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: N J Hopwood; R L Hintz; J M Gertner; K M Attie; A J Johanson; J Baptista; J Kuntze; R M Blizzard; J F Cara; S D Chernausek Journal: J Pediatr Date: 1993-08 Impact factor: 4.406
Authors: Kerstin Albertsson-Wikland; A Stefan Aronson; Jan Gustafsson; Lars Hagenäs; Sten A Ivarsson; Björn Jonsson; Berit Kriström; Claude Marcus; Karl Olof Nilsson; E Martin Ritzén; Torsten Tuvemo; Otto Westphal; Jan Aman Journal: J Clin Endocrinol Metab Date: 2008-08-26 Impact factor: 5.958
Authors: G A Kamp; J J J Waelkens; S M P F de Muinck Keizer-Schrama; H A Delemarre-Van de Waal; L Verhoeven-Wind; A H Zwinderman; J M Wit Journal: Arch Dis Child Date: 2002-09 Impact factor: 3.791